araag2/HINT huggingface dataset:
Clinical trial NCT01430442 (phase 2, status: completed)
Conditions: migraine, acute treatment of migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: rimegepant, placebo, sumatriptan
SMILES: N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patient with at least 1-year history of migraines (with or without aura) including the
             following:

               -  Migraine attacks more than 1 year with age of onset prior to 50 years of age

               -  Migraine attacks, on average, last about 4 - 72 hours if untreated

               -  No more than 8 attacks of moderate to severe intensity per month within last 3
                  months

               -  Patient must be able to distinguish migraine attacks from tension/cluster attacks
                  and must have consistent migraine headaches of at least 2 migraine headaches
                  attacks of moderate to severe intensity in each of the last 3 months

               -  Less than 15 days of headache (migraine or non-migraine) per month in each of 3
                  months prior to screening

          -  Male and female ≥ 18 years and ≤ age 65

          -  No clinically significant abnormality identified on the medical or laboratory
             evaluation

        Key Exclusion Criteria:

          -  Patient has a history of basilar migraine or hemiplegic migraine

          -  Patient does not receive migraine relief from triptan migraine treatment

          -  Medications that may alter the pH of the stomach (acid reducing agents), such as H-2
             antagonists, Proton Pump inhibitors (PPI), antacids

          -  History of ergotamine or triptan intake greater than/equal 10 days per month on a
             regular basis for greater than 3 months

          -  History of non-narcotic analgesic intake on greater then/equal 15 days per month for
             greater than/equal 3 months
Clinical trial NCT00238745 (phase 2, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: bazedoxifene, placebo
SMILES: CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be postmenopausal and diagnosed as osteoporosis based on bone mineral density
             and/or vertebral fracture.

        Exclusion Criteria:

          -  Diseases which possibly induce secondary osteoporosis or osteopenia and affect on bone
             metabolism.
Clinical trial NCT00388518 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: actos, placebo, aleglitazar
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  type 2 diabetes, diagnosed >=1 month of screening;

          -  either drug-naive, or pretreated with a maximum of 2 oral antihyperglycemic agents at
             submaximal doses;

          -  HbA1c <=10.0% at screening, and 7.0-10.0% at pre-randomisation visit.

        Exclusion Criteria:

          -  type 1 diabetes;

          -  currently or previously treated with insulin, a thiazolidinedione, or a dual
             Peroxisome Proliferator Activated Receptor (PPAR) agonist;

          -  clinically significant cardiovascular disease;

          -  Congestive Heart Failure (CHF) New York Heart Association (NYHA) 3-4.
Clinical trial NCT00628095 (phase 2/phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ce-224,535, placebo
SMILES: COC[C@H](O)CN1C(=O)C=NN(C1=O)C1=CC=C(Cl)C(=C1)C(=O)NCC1(O)CCCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis

          -  Incomplete response to methotrexate

        Exclusion Criteria:

          -  Must not be on biologic therapies

          -  No recent infections
Clinical trial NCT00452075 (phase 2, status: terminated)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological documented diagnosis of inoperable, locally advanced,
             recurrent or metastatic (Stage IIIB or Stage IV) NSCLC.

          -  Chemo-naïve patients.

          -  Patients who are in the investigator's opinion not medically suitable for
             chemotherapy.

          -  Measurable disease according to the RECIST criteria.

          -  ECOG performance status of 0 - 3.

          -  Life expectancy of at least 12 weeks.

          -  Patients must be able to take oral medication.

          -  Serum calcium within normal ranges

          -  ≥ 4 weeks since prior surgery or radiation therapy

          -  For all females of childbearing potential a negative pregnancy test must be obtained
             within 48 hours before starting therapy and must use effective contraception

          -  18 years of age or older

          -  Written (signed) Informed Consent to participate in the study

        Exclusion Criteria:

          -  Prior systemic antitumor therapy

          -  Any unstable systemic disease which according to the investigator contraindicates the
             use of the study drug render the subject at high risk from treatment complications
             (including active infection, unstable angina, myocardial infarction within the
             previous month, inflammatory bowel disease, hepatic disease with serum bilirubin ≥ 2
             upper limit of normal (ULN) or AST and/or ALT ≥ 2 x ULN (or ≥ 5 x ULN if clearly
             attributable to liver metastasis), renal disease with acute renal failure or serum
             creatinine ≥ 5 x ULN.

          -  Any other malignancies within 5 years (except for adequately treated carcinoma in situ
             of the cervix or basal or squamous cell skin cancer).

          -  Nursing mothers or pregnant woman.

          -  Hypersensitivity to Tarceva or co-formulants.

          -  Patients with brain metastasis or spinal cord compression that has not yet been
             definitively treated with surgery and/or radiation.

          -  Patients with brain metastasis or spinal cord compression that not are in a stable
             condition despite treatment with steroids.
Clinical trial NCT00304252 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: interferon beta-1a
SMILES: [Na+].[Cl-]
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with an established diagnosis of Crohn's disease who went into remission
             using corticosteroids within 4 weeks before the study

        Exclusion Criteria:

          -  Any other treatment for the maintenance of remission of Crohn's disease
Clinical trial NCT01363986 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab [herceptin]
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    study was prematurely terminated due to difficulties experienced in recruiting patients in a
    reasonable timeframe.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/=18 years of age

          -  Diagnosis of breast carcinoma with HER-2 overexpression

          -  At least one measurable brain metastasis

          -  Patients for whom, according to investigator assessment, whole brain radiotherapy is
             the best therapeutic option

          -  Performance status (WHO) </=2

          -  Life expectancy >/=3 months

        Exclusion Criteria:

          -  Presence of neoplastic meningitis

          -  Any prior radiotherapy to the brain

          -  Patients for whom, according to investigator assessment, stereotactic radiotherapy is
             the best therapeutic option

          -  Previous neoplasms, other than breast carcinoma, within 5 years since enrolment
Clinical trial NCT00523640 (phase 2, status: terminated)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: combination of gemcitabine, capecitabine, and bevacizumab
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    too slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic clear cell renal cell cancer

          -  Measurable disease

          -  Age 18 or older

          -  ECOG performance status of 0 - 1

          -  Blood pressure less than 140/90 on 2 separate occasions not more than 6 weeks prior to
             enrollment and not less than 24 hours apart

          -  Normal organ function

          -  Women of child-bearing potential and men must agree to use adequate contraception

          -  Ability to understand and the willingness to sign a written informed consent document
             and to follow all required study procedures

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
             the study or those who have not recovered from adverse events due to agents
             administered more than 4 weeks earlier

          -  Patients may not have had prior treatment with pyrimidine analogs or VEGF binding
             agents

          -  Patients may not be receiving any other investigational or therapeutic agents

          -  Patients may not be receiving therapeutic anticoagulation with warfarin, its
             congeners, heparin, low molecular weight heparinoids, specific thrombin inhibitors, or
             other similar agents Patients receiving low dose coumadin (1 mg daily) for central
             line patency are eligible

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to treatment start, or anticipation of need for major surgical procedure during
             the course of the study Fine needle aspirations or core biopsies within 7 days prior
             to treatment start are acceptable

          -  Serious, nonhealing wound, ulcer, or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Patients with known brain metastases

          -  Uncontrolled intercurrent illness

          -  Pregnant women

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study
Clinical trial NCT00235989 (phase 2, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: interferon beta 1b (betaseron, bay86-5046), interferon beta 1b (betaseron, bay86-5046), interferon beta 1b (betaseron, bay86-5046), interferon beta 1b (betaseron, bay86-5046)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated statement of informed consent

          -  Completion of Protocol 307000A

          -  Negative serum pregnancy test results

          -  Agreement to adequate contraception, for female patients

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  History of alcohol or drug abuse

          -  Inability to administer subcutaneous injections either by self or by caregiver

          -  Medical, psychiatric or other conditions that compromise the patient's ability to give
             informed consent, to understand the patient information, to comply with the study
             protocol, or to complete the study

          -  Any significant change in the patient's medical condition after enrollment in Study
             307000A which would have lead to his/her exclusion from participation that study
Clinical trial NCT01251354 (phase 2, status: terminated)
Conditions: endometrial cancer
ICD codes: N85.00, N85.01, N85.02, N99.85
Drugs: bn83495
SMILES: NS(=O)(=O)OC1=CC=C2C3=C(CCCCC3)C(=O)OC2=C1
Reason stopped: 
    the futility analysis of study nct00910091 in patients with endometrial cancer shows that the
    primary endpoint will not be reached.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent prior to any study related procedures.

          -  postmenopausal or ovariectomised female patient over 18 years of age.

          -  histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary
             tumour or metastatic disease

          -  patient has received one line of chemotherapy prior to enrolment in the adjuvant or in
             the metastatic setting (including chemoradiotherapy) and progressed after this line of
             chemotherapy

          -  patient has at least one measurable disease site (RECIST criteria version 1.1)

        Exclusion Criteria:

          -  patient has received hormone therapy for endometrial cancer in the adjuvant or
             metastatic setting

          -  patient has received more than one line of chemotherapy in the adjuvant or metastatic
             setting

          -  patient was treated with any other investigational agent within the 3 weeks before
             study entry.

          -  patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade
             (NCI CTCAE) or QTcF interval >460 msec.
Clinical trial NCT02829775 (phase 2/phase 3, status: completed)
Conditions: chronic myelogenous leukemia, malignant melanoma, renal cell carcinoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: pegylated interferon alfa-2a, recombinant interferon alfa 2a
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have completed protocol NO15753, NO15764, NO16006 or NO16007 and
             responded to treatment at the end of the trial as defined in the parent protocol

          -  CML participants must have a confirmed cytogenetic complete response within 2 months
             of entering the extension study. MM and RCC participants must have tumour assessments
             verifying stable or better response within 2 months of entering the extension study

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Refusal to use adequate contraceptive measures among men and women of childbearing
             potential
Clinical trial NCT01077245 (phase 2, status: withdrawn)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: miya-bm fine granules (cbm588), placebo fine granules (without cbm588)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult of either gender, aged 18-80 years old inclusive

          -  Meets the case definition of CDI - recent history of diarrhea with presence of C.
             difficile toxin or pseudomembranous colitis; and no other known etiology of diarrhea
             (e.g. other enteric pathogen, other intestinal disease)

          -  CDI treated with metronidazole or vancomycin

          -  If female and of reproductive potential, subject must not be pregnant (negative
             pregnancy test at time of screening) or breast-feeding, and currently using a reliable
             method of birth control

        Exclusion Criteria:

          -  Has other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal
             disease)

          -  Has a history of acute pancreatitis within the last 3 months

          -  Has a history of chronic intestinal disease (e.g. Crohn's disease, ulcerative colitis)

          -  Is unable to complete a daily study diary (mental incapacity, head trauma, etc.)

          -  Has presence of toxic megacolon or ileus

          -  Has presence of colostomy, naso-gastric tube, or indwelling central line

          -  Has history of abdominal surgery within the previous 3 months (from time of
             enrollment)

          -  Has recent history of other investigational drug use within 30 days of enrollment
             visit

          -  Has planned investigational drug use while participating in this study

          -  Is known to have HIV infection or AIDS or other immunosuppressive disease

          -  Has taken systemic immunosuppressive drugs within 60 days of enrollment

          -  Is currently taking or is planning to use an oral probiotic, other than yogurt, during
             the study

          -  Has a known allergy to any component of MIYA-BM Fine Granules or placebo

          -  Is unavailable for follow-up visits

          -  At enrollment, has any social or medical condition, or psychiatric illness that, in
             the opinion of the investigator, would preclude provision of informed consent, make
             participation in the study unsafe, complicate interpretation of the study outcome
             data, or otherwise interfere with achieving the study objectives
Clinical trial NCT00201435 (phase 2/phase 3, status: completed)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: paclitaxel weekly in combination with capecitabine, docetaxel every 3 week in combination with capecitabine
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria: Morphologically proven breast carcinoma

        Written informed patient consent Measurable and/or evaluable disease Measurable disease is
        defined as least one lesion that can be accurately measured in at least one dimension as
        ≥20 mm by conventional techniques, or as ≥10 mm by spiral CT scan) as defined in section 8.

        Evaluable metastases. Lytic bone metastases as only site of recurrence are allowed and can
        be evaluated for response according to the WHO-criteria for reporting on response in bone
        metastases.

        Age 18 years or older ECOG Performance Status 0-2 Life expectancy of at least three months
        Adequate cardiac functions

        Adequate hematological, renal and hepatic functions, defined as:

        White blood cell count > 3.9 x 109/L Trombocytes > 100 x 109/L Serum creatinine < 1.25 x
        ULN* Bilirubin < 1.5 ULN If alkaline phosphatases (ALP) is normal ALAT < 3.5 ULN ASAT < 3.5
        ULN If alkaline phosphatases (ALP) is > 2.5 ULN ALAT < 1.5 ULN ASAT < 1.5 ULN

        -

        Exclusion Criteria: Recurrence-free interval less than one year, if previous adjuvant or
        neoadjuvant regimen contained a taxane

        Neoplasm other than breast carcinoma, except for non-melanoma skin cancer or curatively
        treated carcinoma in situ of the cervix, diagnosed during the past five years

        Pregnancy or lactation

        Known brain metastases

        Preexisting motor or sensory neuropathy ≥ grade 2 according to NCI CTC 2.0 criteria (severe
        paresthesia and/or mild weakness, or worse)

        Severe hepatic or renal impairment (for capecitabine: calculated creatinine clearance below
        30 ml/min; for calculation, see p. 5.1.4) not allowing for adequate use of the proposed
        regimens

        History of known dihydropyrimidine dehydrogenase (DPD) deficiency (severe reaction on
        previous treatment with fluorouracil)

        Active infection or other serious underlying medical condition which would impair the
        ability of the patient to receive protocol treatment, including prior allergic reactions to
        drugs containing cremophor, such as teniposide, cyclosporine or vitamin K

        Dementia or significantly altered mental status that would prohibit the understanding and
        giving of informed consent.

        -
Clinical trial NCT00723957 (phase 2, status: completed)
Conditions: advanced/metastatic non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ixabepilone, 32 mg/m^2, paclitaxel, 200 mg/m^2, carboplatin (area under the concentration curve [auc] 6)
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer (NSCLC)(squamous cell,
             adenocarcinoma, large cell, or bronchoalveolar carcinoma)

          -  Stage IIIB NSCLC with pleural effusion, Stage IV NSCLC, or recurrent disease following
             surgery with or without radiation therapy

          -  Available paraffin-embedded tissue to measure the expression levels of βIII tubulin

          -  Disease measurable by Response Evaluation Criteria in Solid Tumors, with at least 1
             target lesion situated outside any previous radiotherapy field

          -  Karnofsky performance status of 70-100

          -  Life expectancy of at least 3 months

          -  Men and women, ages 18 years and older

        Exclusion Criteria:

          -  Uncontrolled brain metastases

          -  Peripheral neuropathy greater than Grade 1

          -  Fewer than 4 weeks from prior radiation therapy or locoregional surgeries to
             randomization date (less than 1 week from focal/palliative radiotherapy or minor
             surgery)

          -  Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of
             the cervix

          -  Known HIV-positive status

          -  Absolute neutrophil count lower than 1500 cells mm^3

          -  Total bilirubin level higher than upper limit of normal (ULN) as defined by the
             institution (with the exception of elevation due to Gilbert's syndrome)

          -  Aspartate transaminase or alanine transaminase level higher than 2.5*ULN

          -  Serum creatine level of 1.5 mg/dL or higher

          -  Renal function with a creatinine clearance of less than 50 mL/min (as calculated with
             the Cockcroft and Gault equation)

          -  Any prior antineoplastic systemic regimens.